论文部分内容阅读
目的探讨华蟾素联合folfox6方案对晚期消化道肿瘤患者T细胞亚群的影响效果。方法选择58例晚期消化道肿瘤患者,随机分为华蟾素联合folfox6方案治疗组(简称观察组)以及单纯folfox6方案治疗组(简称对照组),疗程结束后观察两组患者的临床疗效、毒副反应以及检测外周调节性T细胞。结果治疗后,观察组有效率48.28%优于对照组31.03%,差异具有统计学意义(P<0.05)。从症状来看,治疗后,观察组出现毒副反应者占34.48%,低于对照组62.07%,差异具有统计学意义(P<0.05);从中性粒细胞情况看,与对照组比较,观察组0度比例升高明显,Ⅲ度比例降低明显,差异具有统计学意义(P<0.05,P<0.01)。同时,治疗后,与对照组比较,观察组的外周血CD4+T细胞降低明显,CD4+CD25+T细胞、CD4+CD25+Foxp 3 T细胞则增加明显,差异均具有统计学意义(P<0.05)。结论华蟾素联合folfox6方案治疗晚期消化道肿瘤,不仅疗效佳,安全性高,而且可有效改善调节性T细胞的数量,进而调控免疫功能。
Objective To investigate the effect of cinobufacini combined with folfox6 on T cell subsets in patients with advanced gastrointestinal cancer. Methods Fifty-eight patients with advanced gastrointestinal cancer were enrolled and divided randomly into two groups: cinobufotalin combined with folfox6 (simple observation group) and folfox6 alone (control group). After treatment, the clinical efficacy, toxicity Side effects and detection of peripheral regulatory T cells. Results After treatment, the effective rate in observation group was 48.28%, which was significantly higher than that in control group (31.03%) (P <0.05). From the symptom point of view, after treatment, there were 34.48% of patients in the observation group, which was lower than 62.07% of the control group (P <0.05); from the situation of neutrophils, compared with the control group, The proportion of 0 degree increased significantly, the degree of Ⅲ degree decreased significantly, the difference was statistically significant (P <0.05, P <0.01). At the same time, compared with the control group, the CD4 + T cells in the peripheral blood of the observation group decreased significantly, the CD4 + CD25 + T cells and CD4 + CD25 + Foxp3 T cells increased significantly (P < 0.05). Conclusions Cinobufacini combined with folfox6 regimen in the treatment of advanced gastrointestinal tumors not only has good curative effect and high safety, but also can effectively improve the number of regulatory T cells and further regulate the immune function.